丙型肝炎抗病毒治疗对儿童生长发育的影响研究

摘要

儿童慢性丙型肝炎的治疗一直是临床上十分棘手的问题.最近美国食品与药品管理局批准了聚乙二醇干扰素-α2a联合利巴韦林用于儿童患者的治疗,已有大型的前瞻性临床研究证明其疗效及安全性,但在也发现药物对儿童的生长发育存在一定影响.因此,临床上对儿童丙型肝炎患者的治疗更须慎重考虑,避开儿童发育的重要时期(新生儿及青春期)进行治疗,并做好随访,及时评估药物对儿童的影响.%Treatment of children with chronic hepatitis C has been a very difficult problem clinically. Recently the U. S. Food and Drug Administration has approved pegylated interferon-α 2a and ribavirin for the treatment of pediatric patients. Meanwhile large prospective clinical studies have proven the efficacy and safety of these drugs, but also find certain effect of the drugs on the growth of children. Therefore, the clinical treatment of children with chronic hepatitis C must be carefully handled to avoid the delivery of treatment during important development periods (neonatal and adolescent periods). The treated children should be followed up to timely assess the effect of drugs on children.